NKG2D is a lectin-like type II transmembrane protein also known as CD314. It is expressed on NK cells, a subset of CD8⁺ T cells, γ/δ T cells and NK1.1⁺ T cells, as well as in vitro induced LAK cells. NKG2D serves as a stimulatory immunoreceptor to activate NK cells via the non-covalently associated DAP10 or DAP12 adaptor. Several molecules have been identified as the ligands for NKG2D, including minor histocompatibility molecule, H60, UL16-binding protein-like transcript 1 (Mult1, and a family of retinoic acid early transcript 1 (Rae1) in mice, MHC class-I chain-related protein A (MICA), MICB, and UL16-binding proteins (ULBPs) in humans. present in both mice and humans. NKG2D ligands trigger cytokine (IFN-γ, GM-CSF, TNF-α, MIP1β and others) and granzyme release from NK cells. The C7 antibody has been reported to block NK cell killing of targets expressing NKG2D ligands and induce redirected lysis.

PRODUCT DETAILS

Clone: C7

Antibody Type: Monoclonal

Reactivity: Mouse

Format: PE

Host: Armenian Hamster

Isotype: IgG

Applications: FC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.